Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amidst ESA Upheaval, FDA Used Mircera Review To Outline Trial “Wish List”

Executive Summary

FDA's review of Roche's Mircera BLA became a forum for the agency to set forth a "wish list" for future development of erythropoietin stimulating agents that reflected the seismic upheavals in the conventional understanding of the safety of erythropoietin products

You may also be interested in...

Cochran Collaboration ESA Meta-Analysis Underscores Survival Risk

A meta-analysis of patient level data from over 10,000 clinical trial patients suggests that use of erythropoiesis-stimulating agents may have an adverse survival impact in the still-approved uses in supportive care for oncology

Roche Mircera Launch Blocked By Permanent Injunction

Ruling comes just ahead appeals-court hearing on epoetin follow-on.

The Future Of ESAs – Is It All CKD Now?

Takeda and Affymax revise Hematide program to stop development for chemotherapy-induced anemia and focus on anemia related to chronic kidney disease.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts